Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 16/20 | 0.62 |
| ▸ | NPY1R | P25929 | 9/20 | 0.62 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.62 |
| ▸ | NPY2R | P49146 | 5/20 | 0.62 |
| ▸ | KISS1R | Q969F8 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29641154 | 0.85 | NPY4R (0.76) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29641080 | 0.83 | NPY4R (0.80) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL29641081 | 0.81 | NPY4R (0.78) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL14520583 | 0.81 | NPY4R (0.78) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL13188655 | 0.81 | NPY4R (0.78) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL370279 | 0.81 | NPY4R (0.78) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29641192 | 0.81 | NPY4R (0.78) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL1373207 | 0.80 | NPY4R (0.64) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL1373212 | 0.80 | NPY4R (0.64) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL29981508 | 0.80 | NPY4R (0.75) | NPY4RNPY1RNPY5RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11261213-B2 | Crystalline bis- and tris-hydrochloride salt of elamipretide | STEALTH BIOTHERAPEUTICS INC. (US) | 2022-03-01 | — | — | US | disclosed |
| US-11261213-B2 | Crystalline bis- and tris-hydrochloride salt of elamipretide | STEALTH BIOTHERAPEUTICS INC. (US) | 2022-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11261213-B2 | Crystalline bis- and tris-hydrochloride salt of elamipretide | ANPEP, DNPEP, DPP4 | NPY4R 250/4885NPY1R 686/4885NPY5R 1118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.